Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.

Diabetes, obesity & metabolism 20121001

Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.

Current medical research and opinion 20121001

Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.

Bioanalysis 20120801

Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden.

Primary care diabetes 20120701

Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.

Drug metabolism and disposition: the biological fate of chemicals 20120701

Pharmacokinetic study of saxagliptin in healthy Chinese subjects.

Clinical drug investigation 20120701

Drug-induced hypoglycaemia in type 2 diabetes.

Expert opinion on drug safety 20120701

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.

Diabetes, obesity & metabolism 20120601

An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.

Current diabetes reviews 20120501

Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage.

Diabetes, obesity & metabolism 20120401

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

Diabetes & metabolism 20120401

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.

Current medical research and opinion 20120401

Dipeptidyl peptidase-4 inhibitors: 3 years of experience.

Diabetes technology & therapeutics 20120401

Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: method validation and overcoming specific and non-specific binding at low concentrations.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120315

Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.

Diabetes/metabolism research and reviews 20120301

Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.

Annals of medicine 20120301

Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.

Clinical drug investigation 20120301

Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.

Expert opinion on drug metabolism & toxicology 20120301

Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.

Drugs 20120122

The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland.

Diabetes technology & therapeutics 20120101

Metformin + saxagliptin for type 2 diabetes.

Expert opinion on pharmacotherapy 20120101

A pharmacometric approach to quantify the impact of chronic kidney disease and hemodialysis on systemic drug exposure: application to saxagliptin.

Journal of clinical pharmacology 20120101

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.

Cardiovascular diabetology 20120101

A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.

Pharmacoepidemiology and drug safety 20120101

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.

BMC pharmacology 20120101

Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system.

Revista da Associacao Medica Brasileira (1992) 20120101

Kinetic and mechanistic insight into the thermodynamic degradation of saxagliptin.

The Journal of organic chemistry 20111216

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

International journal of clinical practice 20111201

[Incretin-based therapy for treating patients with type 2 diabetes].

Orvosi hetilap 20111127

Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial.

Diabetes research and clinical practice 20111101

The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.

American heart journal 20111101

[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].

Orvosi hetilap 20110911

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.

Diabetes, obesity & metabolism 20110901

Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: predictive factors of the treatment response in type 2 diabetes.

Annales d'endocrinologie 20110901

Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus.

The American journal of cardiology 20110802

Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus.

Clinical therapeutics 20110801

Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects.

Diabetes, obesity & metabolism 20110701

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.

British journal of clinical pharmacology 20110701

Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.

Postgraduate medicine 20110701

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment.

Diabetes, obesity & metabolism 20110601

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks.

Diabetes, obesity & metabolism 20110601

Place in therapy for liraglutide and saxagliptin for type 2 diabetes.

Southern medical journal 20110601

Recent diabetes issues affecting the primary care clinician.

Southern medical journal 20110601

Enzymatic preparation of 5-hydroxy-L-proline, N-Cbz-5-hydroxy-L-proline, and N-Boc-5-hydroxy-L-proline from (α-N-protected)-L-ornithine using a transaminase or an amine oxidase.

Enzyme and microbial technology 20110506

An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.

Contemporary clinical trials 20110501

DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.

Diabetes care 20110501

Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus.

Current medical research and opinion 20110401

Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.

Clinical pharmacokinetics 20110401

FDA's first active medical product surveillance eyes antidiabetic-MI link.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110401

Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.

Diabetes & vascular disease research 20110401

Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks.

Diabetes & vascular disease research 20110401

Saxagliptin/metformin (kombiglyze XR) for type 2 diabetes.

The Medical letter on drugs and therapeutics 20110321

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.

Hospital practice (1995) 20110201

Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions.

Prescrire international 20110201

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Postgraduate medicine 20110101

Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats.

Journal of atherosclerosis and thrombosis 20110101

Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.

Clinical drug investigation 20110101

DPP-4 inhibitors: what may be the clinical differentiators?

Diabetes research and clinical practice 20101101

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.

International journal of clinical practice 20101101

Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects.

Journal of clinical pharmacology 20101001

Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin.

Current medical research and opinion 20101001

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.

Diabetes/metabolism research and reviews 20101001

Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100915

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.

Clinical pharmacokinetics 20100901

Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.